echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Novavax's new crown vaccine has an overall effective rate of 90%, which is equally effective against multiple variant viruses

    Novavax's new crown vaccine has an overall effective rate of 90%, which is equally effective against multiple variant viruses

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The US biotechnology company Novavax said on Monday that its new coronavirus vaccine (NVx-CoV2373) has been proven safe in phase III clinical trials with nearly 30,000 participants in 119 locations in the United States and Mexico.
    The overall effective rate was 90.
    4%, and it was found that the effectiveness of the two doses of vaccine in preventing moderate and severe diseases was 100%, and the effective rate of certain variants was 93%
    .

    The company's analysis evaluated 77 confirmed new coronavirus infections among the 29960 participants in the trial
    .

    Novavax said that 63 cases of new coronary pneumonia were observed in the placebo group and 14 cases were observed in the group receiving two doses of the vaccine, which indicates that the overall vaccine efficacy is 90.
    4%
    .

    The most common side effects are fatigue, headache, muscle pain and pain at the injection site, which usually last no more than two or three days
    .

    The vaccine is equally effective against a variety of variant viruses, including the variant virus first discovered in the UK, and high-risk groups including the elderly and people with other health problems
    .

    The data of the vaccine in the United States and Mexico are similar to those in the United Kingdom at the beginning of the year, and its effectiveness in protecting people from the new coronavirus infection is 89.
    3%
    .

    In the third quarter of this year, it is planned to apply for approval to the regulatory agencies in the United States and Europe
    .

    If approved, the company can produce 100 million doses of vaccine per month before the end of the third quarter; by the end of the year, it can produce 150 million doses per month
    .

    Novavax new crown vaccine does not require extremely low temperature storage.
    This vaccine can be stored stably in an environment of 2 to minus 8 degrees Celsius
    .

    This means that the vaccine will be easier to send to countries with relatively backward health infrastructure
    .

    Dr.
    Gregory Glenn Novavax president of research and development said in a press release late test "have confirmed NVX-CoV2373 encouraging tolerance and security"
    .

    "These data show consistent, high-level efficacy, and reaffirm the vaccine's ability to prevent new coronary pneumonia during the continued genetic evolution of the virus
    .

    " Anti-IgG spike protein response levels in each treatment group, C.
    Keech, et al.
    Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
    The New England Journal of Medicine.
    September 2,2020.
    DOI: 10.
    1056/NEJMoa2026920 published in New England Medicine in September last year.
    The results show that In the case of adjuvants, the average geometric titer (GMT) of neutralizing antibodies triggered by a dose of 5μg of NVX CoV2373 and a dose of 25μg of NVX CoV2373 are equivalent, with peak values ​​greater than 3300, which shows that the induced neutralization response can exceed most Serum reaction levels in patients recovering from symptomatic new coronary pneumonia
    .

    At 35 days, from the existing data, NVX-CoV2373 is safe, and the immune response it causes exceeds the serum level of patients with new coronary disease during the recovery period
    .

    The CD4+T cell response induced by Matrix-M1 adjuvant is biased towards the Th1 phenotype
    .

    As a large number of vaccines are already available in the United States, the government may donate Novavax doses to other countries
    .

    The US Biden government has pledged to donate at least 20 million doses of Covid vaccines produced by Pfizer-BioNTech, Moderna and Johnson & Johnson, as well as 60 million doses of AstraZeneca vaccines that have not yet been approved for use in the United States
    .

    Earlier this month, the White House announced that it would lift restrictions as part of the National Defense Production Act, which gives the United States priority for vaccines developed by AstraZeneca, Sanofi and Novax
    .

    Novavax said on Monday that it is still expected to reach a monthly production capacity of 100 million doses by the end of the third quarter and a monthly production capacity of 150 million doses by the fourth quarter of 2021
    .

    The company's stock price rose by more than 9% in premarket trading
    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.